Novel Medical Device for Pharmacological Therapy

NCT06938750 | Recruiting

• 1 other identifier: SecHold Baby
• Study Type: interventional
• Target: 262
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.

Conditions

Vascular Access; Vascular Access Complication; Vascular Access Complications; Catheter Malfunction; Catheter Infection; Therapeutic Drug Management; Nurse; Nurse Based Care Management; Innovative Procedures

Keywords

VASCULAR ACCESS; CATHETER; THERAPY; COMPLICATION; DEVICE; CENTRAL VASCULAR ACCESS

Outcome Measures

Primary Outcomes (2)

• To reduce the risk of complications associated with the number of pharmacological errors.

  Recognize the number of pharmacological errors (DRUG INTERACTION, WRONG DRUG, WRONG DOSAGE, WRONG SPEED) that have occurred

  day 1, day 7, day 14, at 6 months after placement and start of the study

• To reduce complications associated with accidental catheter withdrawals.

  Number of complications associated with accidental catheter withdrawals during the study period

  day 1, day 7, day 14, at 6 months after placement and start of the study

Secondary Outcomes (1)

• Reduce complications associated with venous catheter placement and maintenance (thrombosis, phlebitis, catheter obstruction).

  day 1, day 7, day 14, at 6 months after placement and start of the study

Other Outcomes (1)

• Improved satisfaction of healthcare professionals operating the device.

  day 1, day 7, day 14, at 6 months after placement and start of the study

Study Arms (2)

CONTROL

NO INTERVENTION

FIXATION OF VASCULAR ACCESSES WITH INFUSION OF THERAPY MAINTAINED IN THE TRADITIONAL WAY, DIRECTLY TO A THREE-WAY TAP AND EXTENSION FOR CONNECTION TO A CENTRAL DEVICE.

INTERVENTION

EXPERIMENTAL

FIXATION OF VASCULAR ACCESSES WITH INFUSION OF THERAPY MAINTAINED IN THE TRADITIONAL WAY, DIRECTLY TO THREE-WAY TAP AND EXTENSION FOR CONNECTION TO CENTRAL DEVICE INCORPORATING THE SECHOLD GRIP SYSTEM FOR ATTACHMENT OF MULTIPLE DROPPERS TO IT, WITH LABELING AND ATTACHMENT TO BED/CRADLE, DROPPER STICK OR PATIENT/CARRIER CLOTHING.

Device: SECHOLD DEVICE

Interventions

SECHOLD DEVICE DEVICE

PLACEMENT OF A MULTIPLE THERAPY GRIPPING DEVICE TO FIX THE DRIPPER SYSTEMS ALONG ITS PATH TO SOME SURFACE OR SPACE, AVOIDING IT TO REMAIN IN THE AIR, WITHOUT MARKING OR LABELING AND FAVORING ITS ORGANIZATION. SECHOLD is a vascular access fixation device designed for critical clinical environments such as ICU and operating rooms. It allows the simultaneous connection of 3-6 parenteral therapies to the same vascular access, ensuring clear and protocolized identification of each drug by means of labels with name, concentration and infusion range, in addition to a universal color code. This reduces the risk of drug administration errors and facilitates optimal visualization of essential information. SECHOLD also organizes infusion systems connected to the same vascular access, preventing knots and pulls that can compromise catheter integrity in case of accidental infusion bag drops.

INTERVENTION

Eligibility Criteria

• Age: 1 Year+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• patients admitted to the intensive care unit
• patients with authorization to take part in the study

You may not qualify if:

• Patients with pre-existing medical conditions: Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies, could be excluded.
• Active infection patients: Any patient with vascular access site infections or systemic infections may be excluded to avoid complications.
• Inability to give informed consent: Patients who are unable to understand or consent to participate in the study.

Sponsors & Collaborators

• Fundacion Miguel Servet: lead

Study Sites (1)

Hospital Universitario de Navarra

Pamplona, Navarre, 31005, Spain

RECRUITING

Study Officials

• Marta M Ferraz-Torres, PHD

  Fundación Miguel Servet

  PRINCIPAL INVESTIGATOR

Central Study Contacts

marta M FERRAZ-TORRES, PHD

CONTACT

+34628813974; marta.ferraz.torres@navarra.es

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: A clinical trial was carried out in an intensive care unit of the University Hospital of Navarra, a tertiary hospital reference center in intensive care in Navarra, in the north of Spain; where the use and clinical validation process of a newly created device registered by European patent as a utility model was implemented. This study was made over a period of 6 months, from June 2021 to December of the same year; after internal authorization from the center where the clinical validation process has been carried out and from the local ethics committee (pyto2019/47).

Study Record Dates

• First Submitted: April 4, 2025
• First Posted: April 22, 2025
• Study Start: January 20, 2023
• Primary Completion: January 31, 2026
• Study Completion (Estimated): September 20, 2026
• Last Updated: April 22, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)